Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| NUVALENT | 10 | - | -5,48 % | ||
| AVADEL PHARMACEUTICALS | 9 | 6 | +0,50 % | ||
| ZYMEWORKS | 8 | 5 | -5,29 % | ||
| JAZZ PHARMACEUTICALS | 8 | 1 | +2,59 % | ||
| HALOZYME THERAPEUTICS | 5 | 6 | -0,10 % | ||
| ENANTA | 4 | - | -0,90 % | ||
| ESPERION | 4 | - | +0,53 % | ||
| VANDA PHARMACEUTICALS | 3 | - | +16,84 % | ||
| ASCENDIS PHARMA | 3 | - | +0,53 % | ||
| OLEMA PHARMACEUTICALS | 3 | - | +138,94 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17:46 | Travere bei Jefferies: Fokus auf strategisches Wachstum bei seltenen Nierenerkrankungen | - | Investing.com Deutsch | ||
| 17:42 | Halozyme Therapeutics Acquires Elektrofi for $750M | 1 | Contract Pharma | ||
| 17:42 | FDA approves Genmab's EPKINLY combination therapy for follicular lymphoma | 1 | Investing.com | ||
| 17:36 | AbbVie, Genmab win FDA label expansion for Epkinly in follicular lymphoma | 5 | Seeking Alpha | ||
| 17:36 | Genmab A/S: Genmab Announces EPKINLY (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma | 100 | Business Wire | Company Announcement EPKINLY plus rituximab and lenalidomide (EPKINLY R2) is the first and only bispecific-based therapy approved by the FDA for follicular lymphoma in the second-line setting... ► Artikel lesen | |
| 17:26 | Vanda tackles Wegovy-driven vomiting, sparking race to phase 3 | 13 | FierceBiotech | ||
| 17:12 | Insmed Incorporated: European Commission Approves BRINSUPRI (brensocatib) as the First and Only Treatment To Date Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union | 146 | PR Newswire | - Non-Cystic Fibrosis Bronchiectasis (NCFB) Is a Serious, Progressive Lung Disease That Can Lead to Permanent Lung Damagei -
- BRINSUPRI Is a First-in-Disease, First-in-Class DPP1... ► Artikel lesen | |
| 17:10 | Regeneron pledges $2B to convert former magazine factory into drug plant: NY governor | 2 | FiercePharma | ||
| 17:10 | FDA takes issue with AstraZeneca TV ad, citing 'misleading impression' of Farxiga indications | 3 | FiercePharma | ||
| 16:54 | BlackRock discloses 6.88% stake in Avadel Pharmaceuticals | 3 | Investing.com | ||
| 16:54 | Side Effects From Wegovy? This Vanda Pharmaceuticals' Drug Halves Vomiting In Patients | 15 | Benzinga.com | ||
| 16:38 | Viatris: Collaborating to Address Antimicrobial Resistance | 184 | ACCESS Newswire | NORTHAMPTON, MA / ACCESS Newswire / November 18, 2025 / Viatris takes a multi-pronged approach to actively engage in addressing AMR, both by providing access through our portfolio of more than 90 antimicrobials... ► Artikel lesen | |
| 16:26 | Jim Cramer Says Amgen (AMGN)'s New Drug Has Good Data | 7 | Insider Monkey | ||
| 16:24 | Rocket Pharma cut at J.P. Morgan on risks to Danon disease program | 3 | Seeking Alpha | ||
| 16:18 | Citadel Group discloses 2.08% stake in Avadel Pharmaceuticals | 1 | Investing.com | ||
| 16:10 | Avadel Board Labels Lundbeck Acquisition Bid a Superior Proposal | 6 | Zacks | ||
| 16:10 | Alector Stock Plummets 63% in a Month: Here's What You Need to Know | 2 | Zacks | ||
| 16:03 | Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc | 140 | Dow Jones News | DJ Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc
The Vanguard Group, Inc. (IRSH)
Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc
18-Nov-2025 / 14:30 GMT/BST
... ► Artikel lesen | |
| 15:45 | Why Roche's Positive Test Results Sent Olema Pharma Skyrocketing 200% | 18 | Investor's Business Daily | ||
| 15:42 | Goldman Sachs discloses trading activity in Avadel Pharmaceuticals | 5 | Investing.com |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .